SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma,European Respiratory Journal

当前位置： X-MOL 学术 › Eur. Respir. J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma
European Respiratory Journal ( IF 16.6 ) Pub Date : 2019-12-05 , DOI: 10.1183/13993003.01858-2019
Claudia S Cabrera _{1,

2,

3} , Cassandra Nan _{3,

4} , Niklas Lindarck ₅ , Maarten J H I Beekman ₆ , Sofie Arnetorp ₁ , Ralf J P van der Valk ₇

Affiliation

As SABA overuse is associated with exacerbations and mortality, GINA no longer recommends SABA only as a preferred reliever in asthma. A consistent pattern of high SABA use from the SABINA programme would indicate a global public health issue. http://bit.ly/33XDrlb

中文翻译：

SABINA：评估与哮喘中使用短效 β2 受体激动剂相关的处方和临床结果的全球计划

由于 SABA 过度使用与恶化和死亡率相关，GINA 不再仅推荐 SABA 作为哮喘的首选缓解剂。SABINA 计划中 SABA 使用率高的一致模式表明存在全球公共卫生问题。http://bit.ly/33XDrlb

更新日期：2019-12-05

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11